In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine ...

Health and Human Services Secretary Robert F. Kennedy, Jr., has announced new members of the Centers for Disease Control and ...

Some of the panel's new members are anti-vaccine or clearly focus their attention on adverse reactions to vaccines.

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.